Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy

Stock Track04-29

Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.

The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.

This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146903525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146903525","market":"hk","top_or_hot":-1,"title":"Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy","media":"Stock Track","content":"<p>Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.</p><p>The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.</p><p>This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 14:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.</p><p>The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.</p><p>This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1146903525","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146903525","pubTimestamp":1777444041,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.The significant price movement comes after the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|英矽智能盘中大涨5.14%因Rentosertib IPF疗法获中国IND批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146903525","isCrawlerRequest":true}